Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
Virus-like particles(VLPs) are formed by self-assembly of envelop/capsid proteins from viruses. Membrane Proteins can be constituted in-situ with VLPs produced from HEK293 cell cultures. These VLPs concentrate conformationally intact membrane proteins directly on the cell surface and produce soluble, high-concentration proteins perfect for immunization and antibody screening.
The VLPs provide the display of properly folded membrane proteins in their native cellular membrane in a compact size of 100~300 nm diameter (similar to the size of most viruses) making it optimal targets for dendritic cells in vivo and surface attachment for phage display.
Please contact us for detailed information.
Contact us for customized product form or formulation.
This product is supplied and shipped with dry ice, please inquire the shipping cost.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Explore our catalog of therapeutic antibody solutions to find the right products for you! We are dedicated to delivering solutions designed to help you drive innovation and push the boundaries of what therapeutic antibodies can be.
We offer a wide range of cell and gene therapy solutions starting from discovery to the clinic. Explore our wide range of proteins, antibodies, kits, and other assays to accelerate the development of your cell and gene therapy.
Organoid Toolbox is a collection of organoid solutions including ready-to-use organoids, organoid differentiation kits, and a variety of services to accelerate the progress of your drug development project.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
Comprehensive cytokine targets including interleukins, growth factors, chemokines, TNFs, etc. are expressed by HEK293 to ensure their natural structure. Their high purity is verified by SDS-PAGE/HPLC/SEC-MALS and high bioactivity is verified by ELISA/SPR/BLI.
Aneuro provides comprehensive tools for neuroscience research, including neuroscience proteins, pre-formed fibrils (PFFs), neural antibodies, neural factors, and more—aiming to accelerate disease modeling, drug screening, and neural mechanism studies.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Docarpamine | TA-870; TA-8704 | Approved | Tanadopa | Heart Failure | null | 1994-01-01 | Heart Failure | Details | ||
Olanzapine/Fluoxetine hydrochloride | OFC | Approved | Eli Lilly And Company | Symbyax | United States | Bipolar Disorder | Eli Lilly And Company | 2003-12-24 | Depressive Disorder, Major; Bipolar Disorder; Depressive Disorder; Depressive Disorder, Treatment-Resistant | Details |
Zuclopenthixol Hydrochloride | LU-0108 | Approved | Clopixol | Bipolar Disorder; Schizophrenia | null | 1962-01-01 | Schizophrenia; Bipolar Disorder | Details | ||
Methylergometrine Maleate | Approved | Metenarin, Methergine, Ryegonivin, Basofortina, Methylergobrevin | Postpartum Hemorrhage; Uterine Cervical Incompetence; Uterine Hemorrhage; Uterine Inertia | Details | ||||||
Samidorphan/Olanzapine | ALKS-3831 | Approved | Alkermes Plc | Lybalvi | United States | Bipolar Disorder; Schizophrenia | Alkermes Inc | 2021-05-28 | Schizophrenia; Bipolar Disorder; Psychotic Disorders; Bipolar and Related Disorders; Bipolar I Disorder; Alcoholism | Details |
Olanzapine | ALKS-7921; LY-170052; LY-170053; INP-105 | Approved | Eli Lilly And Company | Lanzac, Midax, Zypadhera, Zalasta, Zyprexa, Zyprexa Velotab, Zyprexa Relprevv, Olansek, Zyprexa Zydis, Olanzapine ODF, 再普乐 | EU | Schizophrenia; Bipolar Disorder | null | 1996-09-27 | Emergence Delirium; Anorexia Nervosa; Fasting; Chemotherapy-induced nausea and vomiting; Cachexia; Borderline Personality Disorder; Bipolar II Disorder; Depressive Disorder, Treatment-Resistant; Nausea; Gambling; Vomiting; Autistic Disorder; Bipolar I Disorder; Feeding and Eating Disorders; Postoperative Nausea and Vomiting; Multiple Myeloma; Weight Loss; Malaria, Falciparum; Insulin Resistance; Bipolar Disorder; Anorexia; Opioid-Related Disorders; Neoplasms; Stomach Neoplasms; Depression; Esophageal Neoplasms; Depressive Disorder, Major; Schizophrenia; Biliary Tract Neoplasms; Solid tumours; Hematopoietic stem cell transplantation (HSCT); Substance-Related Disorders | Details |
Phenylpropanolamine Hydrochloride | Approved | Nasadec, Nasathera, Pararhinol | Nasal Obstruction | Details | ||||||
Olanzapine/Hydroxyzine pamoate | Approved | Nausea | Details | |||||||
Stepholidine | Approved | Mainland China | Attention Deficit Disorder with Hyperactivity; Tourette Syndrome; Migraine Disorders; Headache | null | 1995-01-01 | Migraine Disorders; Headache; Attention Deficit Disorder with Hyperactivity; Tourette Syndrome | Details |
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Ecopipam | PSYRX-101; Sch-39166 | Phase 3 Clinical | Merck Sharp & Dohme Corp | Language Disorders; Speech Disorders; Self-Injurious Behavior; Lesch-Nyhan Syndrome; Childhood-Onset Fluency Disorder; Tourette Syndrome; Gambling; Stuttering | Details |
Tavapadon | CVL-751; PF-6649751; PF-06649751 | Phase 3 Clinical | Pfizer Inc, Cerevel Therapeutics Llc | Renal Insufficiency; Parkinson Disease; Hepatic Insufficiency | Details |
Thioridazine | TP-21 | Phase 3 Clinical | Novartis Pharma Ag | Schizophrenia; Anxiety Disorders; Carcinoma, Hepatocellular | Details |
Olanzapine long acting injectable (Teva Pharmaceutical Industries) | TV-44749; TEV-‘749; mdc-TJK; TEV-749 | Phase 3 Clinical | Medincell SA | Schizophrenia | Details |
Olanzapine/samidorphan (Qilu Pharmaceutical) | Phase 3 Clinical | Qilu Pharmaceutical Co Ltd | Schizophrenia | Details | |
PF-06412562 | PF-6412562; PF-06412562 | Phase 2 Clinical | Pfizer Inc | Schizophrenia; Schizophrenia Spectrum and Other Psychotic Disorders; Parkinson Disease | Details |
Mevidalen | LY-3154207 | Phase 2 Clinical | Eli Lilly And Company | Alzheimer Disease; Parkinson Disease; Lewy Body Disease | Details |
TGOF02N | TGOF-02N; TGOF02N; FKF02SC | Phase 2 Clinical | Fabre-Kramer | Schizophrenia | Details |
Docarpamine (Martin Pharmaceuticals) | Phase 2 Clinical | Martin Pharmaceuticals Inc | Gastrointestinal Diseases; Liver Cirrhosis; Mouth Diseases | Details | |
Razpipadon | CVL-871 | Phase 2 Clinical | Pfizer Inc | Dementia | Details |
UCB-0022 | UCB-0022 | Phase 2 Clinical | Ucb Biopharma Srl | Parkinson Disease | Details |
[11C]NNC-112 | [11C]NNC-112 | Phase 2 Clinical | Glaxosmithkline Plc | Diagnostic agents | Details |
Lu-AF-28996 | Phase 1 Clinical | H. Lundbeck A/S | Parkinson Disease | Details | |
asenapine schizophrenia (Livzon Pharmaceutical/LTS Lohmann Therapie-Systeme) | Phase 1 Clinical | Lts Lohmann Therapie-Systeme Ag | Schizophrenia | Details | |
Olanzapine intranasal (Neurelis) | NRL-4; NRL-1004 | Phase 1 Clinical | Neurelis Inc | Bipolar Disorder | Details |
Oxytocin/Methylergometrine Maleate | Phase 1 Clinical | Nanjing Gritpharma Co Ltd | Hemorrhage; Obstetric Labor Complications | Details | |
ITI-333 | ITI-333 | Phase 1 Clinical | Intra-Cellular Therapies Inc | Pain; Mood Disorders; Opioid-Related Disorders | Details |
PF-06730110 | PF-06730110; [18F]MNI-968 | Phase 1 Clinical | Invicro Llc | Nerve Degeneration | Details |
This web search service is supported by Google Inc.